<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737850</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-ITP-III-PED</org_study_id>
    <nct_id>NCT04737850</nct_id>
  </id_info>
  <brief_title>Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia</brief_title>
  <official_title>Safety and Efficacy of Hetrombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopenia：a Randomized, Multicenter, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children&#xD;
      with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of&#xD;
      age. This is a 2 part study. In part A, patients will receive Hetrombopag for 8 weeks. In&#xD;
      part B, all patients will receive Hetrombopag for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, double-blind, randomized, placebo-controlled, and open-label Phase III&#xD;
      study to investigate the efficacy, safety of Hetrombopag in pediatric patients with&#xD;
      previously treated chronic ITP. In Part A, patients will receive Hetrombopag for 8 weeks.&#xD;
      After completing Part A, patients will begin Part B, in which they will be randomized to&#xD;
      receive Hetrombopag or placebo in a 12 week double-blind, placebo-controlled treatment&#xD;
      period, following an open-label 12 week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the main parameters in population PK/PD modeling in Part A</measure>
    <time_frame>from baseline to Week 8</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the main parameters in population PK/PD modeling in Part A</measure>
    <time_frame>from baseline to Week 8</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the proportion of patients with a platelet count ≥50×10^9/L at week 10.</measure>
    <time_frame>from baseline to Week 10</time_frame>
    <description>efficacy in part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events, Serious Adverse Event.</measure>
    <time_frame>form baseline to 28 days after the last dose</time_frame>
    <description>safety in Part B</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>PartA, open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hetrombopag plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PartB, double-blind treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hetrombopag plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus standard of care Part B, double-blind treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag</intervention_name>
    <description>Thrombopoietin receptor agonist</description>
    <arm_group_label>PartA, open-label</arm_group_label>
    <arm_group_label>PartB, double-blind treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with no active pharmaceutical ingredient</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of ITP ≥12 months; Platelets &lt;30×109/L.&#xD;
&#xD;
          2. Subjects who are refractory or have relapsed after at least one prior ITP therapy.&#xD;
&#xD;
          3. Previous therapy for ITP including rescue must have been completed at least 21 days&#xD;
             prior to randomization.&#xD;
&#xD;
          4. Subjects treated with maintenance therapy(such as Corticosteroids, Azathioprine, and&#xD;
             Azathioprine) must be receiving a dose that has been stable for at least 14&#xD;
             days,30days, and 60 days respectively.&#xD;
&#xD;
          5. Written informed consent must be obtained from the patient's guardian and accompanying&#xD;
             informed assent from the patient (for children over 8 years old).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No evidence of other causes of thrombocytopenia.&#xD;
&#xD;
          2. Patients with any prior history of arterial or venous thrombosis, or diagnosis as&#xD;
             thrombophilia.&#xD;
&#xD;
          3. Subjects who have previously received eltrombopag or any other thrombopoietin receptor&#xD;
             agonist within 30 days.&#xD;
&#xD;
          4. ALT, AST, or ALP&gt; 1.5 x upper limit of normal (ULN), DBLI, or Scr &gt; 1.2 x upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          5. PT result exceeds normal by more than ±3s, APTT result exceeds normal by more than&#xD;
             ±10s&#xD;
&#xD;
          6. Suffering from serious, progressive, uncontrolled kidney, liver, gastrointestinal,&#xD;
             endocrine, lung, heart, nervous system, brain, or mental illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tianyou Wang, Ph.D</last_name>
    <phone>010-59616161</phone>
    <email>wangtianyou@bch.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing children's hospital .Capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianyou Wang, PhD</last_name>
      <email>wangtianyou@bch.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

